Current strategies of Adoptive Cell Therapy (ACT) with Tumor-Infiltrating Lymphocytes (TIL) involve the expansion and selection of tumor-reactive CD8+ T cells for infusion into metastatic melanoma patients. This evidence concerns the gene CD8A and metastatic melanoma.